Cardiac Screening Protocols for Cavalier King Charles Spaniels: When, How & Why Regular Heart Checks Save Lives

Why cardiac screening matters in Cavalier King Charles Spaniels

[Cavalier King Charles](https://seniorpet.org/knowledge/breed/cavalier-king-charles-spaniel "Senior Cavalier King Charles Spaniel Health Guide") Spaniels (CKCS) carry a uniquely high risk for myxomatous [mitral valve disease](https://seniorpet.org/knowledge/cavalier-king-charles-spaniel-mitral-valve-disease "Mitral Valve Disease Guide") (MMVD; also called mitral valve degeneration). MMVD is the single most important cardiac condition affecting this breed and is the leading cause of heart failure and cardiac-related death in older Cavaliers. For owners and clinicians, proactive cardiac screening — starting early and continuing regularly — is the single most effective strategy to detect disease before clinical decompensation, to guide treatment decisions, and to make responsible breeding choices that reduce prevalence over generations.

This article is a CKCS‑specific, evidence‑based guide to cardiac screening: what tests to use (auscultation, echocardiography, NT‑proBNP, and thoracic radiographs), when and how often to run them by age, what each test reveals (including key echocardiographic measurements and thresholds), cost comparisons, how to find a veterinary cardiologist, the established MVD breeding protocol for Cavaliers, and how early detection alters outcomes (including the EPIC trial evidence).

Key Statistics & Research Data

• Prevalence and age of onset: Cavalier King Charles Spaniels are one of the highest‑risk breeds for MMVD. Reported estimates indicate that a majority of CKCS have audible mitral murmurs by mid‑life: roughly 50% by 5 years of age and >80–90% by 10 years (breed surveys and ACVIM consensus data) (ACVIM Consensus Statement, 2019; Breed health surveys).
• Contribution to mortality: MMVD is the leading cause of cardiac death in CKCS; breed mortality studies often report MMVD as the most frequent cause of cardiac-related death in Cavaliers (Bureau of Breed Health reports; peer‑reviewed mortality studies).
• EPIC trial (pimobendan benefit): In dogs with preclinical MMVD and radiographic/echocardiographic cardiomegaly (Stage B2), [pimobendan](https://seniorpet.org/knowledge/pimobendan-vetmedin-heart-failure-guide "Pimobendan Heart Failure Guide") significantly delayed onset of congestive heart failure (CHF) and prolonged survival compared with placebo (Boswood et al., 2016, Journal of Veterinary Internal Medicine).
• Screening thresholds used in major trials and guidelines: LA:Ao ratio ≥ 1.6 and normalized LVIDd (LVIDDN) ≥ 1.7 were used to define cardiomegaly in the EPIC trial and are widely used as thresholds for Stage B2 disease (Boswood et al., 2016; ACVIM Consensus 2019).
• NT‑proBNP utility: NT‑proBNP concentrations correlate with severity of MMVD; concentrations above roughly 900–1,100 pmol/L (depending on assay) substantially increase the likelihood of CHF and can guide referral decisions (several clinical diagnostic studies).
• BVA/KC (UK) breeding recommendation: The widely followed breeding protocol for CKCS recommends that dogs intended for breeding be free of a detectable mitral murmur at 5 years of age (auscultation by an accredited veterinarian) — a key population‑level measure to reduce early onset MMVD (BVA/KC Heart Scheme; CKCS breed clubs).

Note: thresholds, prevalence percentages, and assay cutoffs vary with study and assay manufacturer; always interpret in the context of your dog’s clinical picture and local laboratory reference ranges.

The disease in Cavaliers: MMVD is breed‑predominant and progressive

Myxomatous mitral valve disease in CKCS is characterized by progressive thickening and degeneration of the mitral valve leaflets, leading to valve regurgitation (backflow from left ventricle to left atrium), atrial enlargement, increased pulmonary venous pressures, and ultimately congestive heart failure. Cavaliers commonly develop MMVD at younger ages and progress faster than many other breeds — that is why breed‑specific screening is essential.

Clinical signs may be absent for years. When present, signs include a cough, exercise intolerance, decreased appetite, breathing changes (tachypnea or increased respiratory effort), or collapse. However, the earliest and most reliable clinical signal is the development of an audible left‑sided systolic murmur picked up during auscultation.

Screening tests: what each test reveals (and specific thresholds used for CKCS)

Auscultation (heart listening with stethoscope)

- What it reveals: Presence, timing and grade of cardiac murmurs and arrhythmias. In CKCS, a left apical systolic murmur is classically associated with MMVD. - When to start and how often: Annual auscultation starting at 1 year of age is recommended for all CKCS. For higher risk (family history of early MMVD), consider auscultation every 6–12 months beginning at 1–2 years. - Interpretation: Any new systolic murmur should prompt referral for echocardiography. Breeding recommendations: dogs used for breeding should be free of an audible murmur at 5 years of age (BVA/KC/CKCS scheme).

Echocardiography (cardiac ultrasound) — the gold standard

- What it reveals: Direct visualization of mitral valve morphology (thickening, prolapse), quantification of mitral regurgitation, left atrial (LA) and left ventricular (LV) size and function, and Doppler measurements of regurgitant jets. - Key measurements and thresholds used in CKCS (and in EPIC/ACVIM guidance): - LA:Ao ratio (left atrial to aortic root): normal dogs typically <1.5; LA:Ao ≥ 1.6 is used as a cardiomegaly threshold indicating Stage B2 MMVD. - LVIDd normalized (LVIDDN or LVIDdN): normal <1.6; LVIDDN ≥ 1.7 indicates LV dilation consistent with Stage B2 in many studies. - E‑point septal separation (EPSS): an index of LV function and mitral valve motion; increased EPSS suggests dilation or dysfunction (breed‑specific reference ranges apply; interpret in context). - When to get one: Immediately after detection of a murmur greater than grade 2/6, or at baseline in breeding candidates and in CKCS with family history of early disease. For CKCS with no murmur, consider a baseline echocardiogram by age 2–4 for breeding and monitoring. - Frequency: If Stage B1 (murmur but no cardiomegaly) — echo every 6–12 months in CKCS, since progression can be relatively rapid. If Stage B2 (cardiomegaly present), refer to cardiology for therapy decisions and monitor per specialist protocol (often every 3–6 months initially).

NT‑proBNP (blood biomarker of cardiac stretch)

- What it reveals: NT‑proBNP increases with myocardial stretch and correlates with the presence and severity of cardiac disease and CHF. It can be used as a screening adjunct to decide on referral or further imaging. - Typical cutoffs: assay‑dependent; many clinical labs use cutoffs around 900–1,100 pmol/L for differentiating significant cardiac disease/CHF from non‑cardiac causes in dogs. Lower elevations can be seen in early disease; serial increases are important. - When to use: When a murmur or equivocal signs are present and echocardiography is not immediately available, or to monitor progression between echos. In CKCS, an elevated NT‑proBNP merits prompt cardiology referral.

Thoracic radiographs (chest X‑rays) and Vertebral Heart Score (VHS)

- What it reveals: Cardiac silhouette size and pulmonary vasculature; pulmonary edema consistent with CHF; chronic cardiomegaly pattern. - VHS thresholds: general canine normal VHS ≈ 8.5–10.5 vertebrae; breed norms can vary. A VHS above the upper end of the lab/breed reference (commonly >10.5) suggests cardiomegaly, but radiographs are less sensitive than echo for early LA dilation. - When to use: Good baseline test when a murmur is detected, to detect radiographic signs of cardiomegaly or pulmonary edema and to stage patients with suspected CHF. In the EPIC trial, thoracic radiographs were used to define cardiomegaly alongside echo criteria.

Recommended screening frequency by age (CKCS‑specific recommendations)

• Age 1 year: baseline auscultation. If murmur absent and no concerning family history, continue annual auscultation.
• Ages 1–3 years: annual auscultation. If family history of early MMVD, consider an echocardiogram between 2–3 years to establish baseline valve morphology.
• Ages 3–5 years: auscultation every 6–12 months. Consider baseline echocardiography if not previously done; if murmur present, immediate echocardiogram and NT‑proBNP.
• Age 5 years (breeding threshold): For CKCS intended for breeding, documented absence of a mitral murmur at age 5 by an accredited veterinarian is a core requirement in many breeding schemes; many breeders also require echocardiographic clearance.
• Age >5 years: more frequent screening. For CKCS with any murmur, echocardiography immediately and then every 6–12 months depending on stage. If Stage B2, follow cardiologist protocol (often every 3–6 months).
• All ages: any new cough, exercise intolerance, increased resting respiratory rate, syncope, or new murmur should trigger immediate cardiac assessment.

Note: These are CKCS‑focused recommendations; they are more intensive than typical for low‑risk breeds because Cavaliers are high‑risk and often develop MMVD early.

How the tests fit together: a practical screening workflow for CKCS

• Annual auscultation from age 1. If no murmur, repeat annually; if murmur present at any age:

- Obtain echocardiography (gold standard) to quantify valve disease and check LA:Ao and LVIDDN. - Run NT‑proBNP as an adjunct to estimate cardiac stress and to triage urgency for echo. - Obtain thoracic radiographs if signs of CHF suspected or to document cardiomegaly (VHS).

• If echo shows LA:Ao ≥ 1.6 and LVIDDN ≥ 1.7 (Stage B2), refer to a cardiologist for consideration of pimobendan therapy (EPIC evidence) and monitoring.
• For breeding candidates: in addition to auscultation, consider echo even if auscultation is normal, and follow the local breed club/BVA/KC guidance.

Cost comparison (typical US/UK ranges; regional variation is expected)

| Test / Service | Typical cost range (USD) | Typical cost range (GBP) | What you get | |---|---:|---:|---| | Veterinary auscultation (general practice) | $35–$100 | £25–£80 | Physical exam and stethoscope assessment | | Echocardiogram (general practice) | $300–$700 | £200–£600 | 2D/Doppler cardiac ultrasound, basic report | | Echocardiogram + cardiologist exam (ACVIM diplomate) | $400–$1,200 | £300–£900 | Specialist interpretation, detailed report | | NT‑proBNP blood test | $80–$200 | £60–£150 | Biomarker result (lab or POC) | | Thoracic radiographs (3 views) | $150–$350 | £100–£300 | Chest X‑rays and VHS measurement | | Referral/consult visit (cardiology) | $150–$500 | £100–£350 | Specialist consult cost (may include echo) |

Costs will vary by region, clinic type, whether Doppler/equipment is specialist‑grade, and if sedation is required. Many cardiology practices offer package pricing (echo + consult + ECG).

Finding and working with a veterinary cardiologist

• Look for an ACVIM Diplomate in Cardiology (or RCVS/EBVS European specialist). These specialists have advanced training and are experienced with breed‑specific MMVD management in CKCS.
• Ask whether the cardiologist has experience with CKCS and MMVD, how they interpret LA:Ao and LVIDDN in Cavaliers, and whether they offer teleconsult follow‑up for dogs living far from referral centers.
• Bring prior records: previous auscultation notes, prior echos (DICOM if possible), NT‑proBNP results, and radiographs. Serial data are valuable for trend assessment in CKCS.
• Discuss realistic monitoring schedules and quality‑of‑life goals; CKCS owners often prioritize earlier detection and intervention to preserve good years.

The MVD breeding protocol and responsible breeding for Cavaliers

• Goal: Delay onset and reduce prevalence of early severe MMVD in the CKCS population.
• Key element (commonly followed in UK and many breeders worldwide): Dogs intended for breeding should be free of an audible mitral murmur at 5 years of age when examined by an accredited veterinarian; some schemes require two clear parents at 5 years for registration of offspring.
• Many responsible breeders go beyond auscultation: they require echocardiographic screening in breeding stock and prefer parents with echocardiographic confirmation of normal valves or only very mild changes well after 4–5 years.
• Why 5 years? Historically, earlier age thresholds allowed dogs with early MMVD to be bred, perpetuating early-onset disease. The 5‑year auscultation threshold aims to select for later‑onset disease and reduce the genetic load.
• Breeders should also use multi‑axis strategies (health screening for syringomyelia, eye checks, hip/elbow scores) because MMVD is complex and likely polygenic.

How early detection changes outcomes — what the evidence shows

• The EPIC trial (Boswood et al., 2016) is pivotal for CKCS owners and veterinarians: dogs with preclinical MMVD PLUS objective cardiomegaly (LA:Ao ≥ 1.6 and LVIDDN ≥ 1.7) that were treated with pimobendan lived longer and had a delayed onset of congestive heart failure compared to placebo.
• Translation for CKCS: early detection of cardiomegaly on echocardiography captures a window (Stage B2) where medical intervention (pimobendan) is evidence‑based to extend the time until CHF and improve survival and [quality of life](https://seniorpet.org/knowledge/[siamese](https://seniorpet.org/knowledge/breed/siamese "Senior Siamese Cat Health Guide")-cat-quality-of-life "Quality of Life Assessment").
• In addition to medications, early detection allows:

- Closer monitoring for arrhythmias and valve progression, - Timely decision‑making about treatment escalation (diuretics, ACE inhibitors where indicated, antiarrhythmics), - More informed breeding decisions to reduce incidence of early MMVD, - Implementation of owner education and home monitoring (e.g., resting respiratory rate).

Clinical guidelines (ACVIM consensus) now recommend pimobendan for dogs in Stage B2 (objective cardiomegaly) rather than using ACE inhibitors alone in the preclinical stage. Note that not every CKCS with a murmur needs pimobendan — only those meeting the objective cardiomegaly criteria.

Practical counseling points for CKCS owners

• Do not assume "my Cavalier will get a murmur eventually so why test?" — detection before symptoms shifts management options and can materially extend good quality life.
• Record and share murmur grades and dates with your breeder/veterinarian — serial records are valuable.
• Prepare for variable costs: a serious cardiac workup may be an investment, but can prevent emergency hospitalization for CHF and improve longevity.
• For breeders: adhering to the 5‑year murmur‑free guideline and integrating echocardiographic screening in breeding lines is the single most effective strategy to slow down early MMVD inheritance.

Example screening algorithm (CKCS summarised)

• No murmur, age <3: annual auscultation.
• No murmur, age 3–5 and breeding candidate: do baseline echocardiogram and NT‑proBNP; document heart‑clear status for breeding records.
• Murmur detected at any age: NT‑proBNP and echocardiogram. If LA:Ao ≥1.6 or LVIDDN ≥1.7 → Stage B2 → cardiology referral and discuss pimobendan.
• Signs of CHF (tachypnea, cough at rest, pulmonary crackles): urgent radiographs and emergency cardiology.

Limitations and caveats

• Assay variability: NT‑proBNP thresholds differ by assay and lab; use lab‑specific reference ranges.
• Breed variability in radiographic VHS: VHS is a helpful adjunct but less sensitive than echo for early LA enlargement; always combine tests.
• Not every CKCS will progress at the same rate; genetics, environment, and comorbidities influence progression.
• There is no simple genetic test for MMVD yet — breeding decisions require phenotypic screening and long‑term commitment.

Key Takeaways

• CKCS are at very high risk for early‑onset myxomatous mitral valve disease; proactive, breed‑specific cardiac screening saves lives and preserves quality of life.
• Start annual auscultation at 1 year of age; any new murmur should prompt NT‑proBNP and echocardiography immediately.
• Echocardiography is the gold standard: LA:Ao ≥ 1.6 and LVIDDN ≥ 1.7 identify cardiomegaly (Stage B2) where pimobendan has proven benefit (EPIC trial).
• NT‑proBNP and thoracic radiographs are valuable adjuncts: NT‑proBNP for triage and monitoring, radiographs for detecting CHF and calculating VHS.
• For breeding Cavaliers, documented absence of a mitral murmur at 5 years (and preferably echocardiographic clearance) is a cornerstone of responsible programs to reduce early MMVD.
• Work with an ACVIM Diplomate cardiologist experienced with CKCS when murmurs, elevated biomarkers, or echocardiographic cardiomegaly are present to optimize monitoring and therapy.
• Early detection and surveillance change both individual outcomes (delay CHF, prolong survival) and population outcomes (improve breeding selection), making regular heart checks an essential duty for every CKCS owner.